The Bio-Rad Geenius™ HIV 1/2 Supplemental Assay has been developed for HIV-1 and HIV-2 differentiation and confirmation.

On behalf of CEPHIA, Dr. S. Keating presented the following poster at CROI 2014 earlier this year.

Abstract:

The Bio-Rad Geenius™ HIV 1/2 Supplemental Assay has been developed for HIV-1 and HIV-2 differentiation and confirmation.

Recently an algorithm was developed to perform HIV-1 recency estimations using this same technology.

This immunochromatographic test detects antibodies to HIV-1 (p31, gp160, p24, p41), HIV-2 (gp36, gp140) antigen bands and protein A (control band) bound to the membrane solid phase and uses protein A conjugated to colloidal gold dye particles for band detection. The HIV band intensity during IgG antibody evolution in HIV infection is captured by the camera in the Geenius™ reader and analyzed using Bio-Rad proprietary image analysis software. Using a 2500-member evaluation panel we have calculated the mean duration of recent infection and the false recent rate.  The Geenius test format not only allows for HIV 1/2 antibody confirmation and differentiation but can also be used to inform newly diagnosed individuals and their health care providers of the likely duration of infection to understand recency in a population.

Poster available here.